


TMI-1

Chemical Properties

CAS No. :	287403-39-8
Formula:	C17H22N2O5S2
Molecular Weight:	398.5
Storage:	Keep away from direct sunlight,Store at low temperature Powder: -20°C for 3 years In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



Biological Description

Description	TMI-1 (WAY-171318), a novel orally active inhibitor of ADAM17 (TACE) and MMP, induces tumor apoptosis in a breast cancer.
Targets(IC50)	Apoptosis,MMP,Caspase,Interleukin,TNF
In vitro	TMI 1 inhibits LPS-induced TNF- α secretion in Raw and THP-1 cells (IC50s = 40 and 200 nM, respectively), as well as in isolated human monocytes and whole blood (IC50s = 190 and 300 nM, respectively).[1] It inhibits the production of TNF- α ex vivo in synovium isolated from the inflamed joints of patients with rheumatoid arthritis with IC50 values of less than 100 nM without inhibiting TNF- α expression in vitro.[3]
In vivo	TMI 1 inhibits LPS-induced TNF- α production in mice (ED50 = 5 mg/kg) and reduces disease severity in mouse models of collagen-induced arthritis. It also decreases cell viability of (ED50s = 1.3-8.1 μ M), and induces caspase-3/7 activity in, a variety of cancer cell lines and induces tumor apoptosis and reduces tumor growth in an MMTV-ErbB2/neu mouse model of breast cancer when administered at a dose of 100 mg/kg.[3]

Solubility Information

Solubility	DMSO: 35.9 mg/mL (90.09 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5094 mL	12.5471 mL	25.0941 mL
5 mM	0.5019 mL	2.5094 mL	5.0188 mL
10 mM	0.2509 mL	1.2547 mL	2.5094 mL
50 mM	0.0502 mL	0.2509 mL	0.5019 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Zhang Y, et al. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor- α -converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. *J Pharmacol Exp Ther.* 2004;309(1):348-355.
- Moss ML, et al. Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening. *Anal Biochem.* 2007;366(2):144-148.
- Mezil L, et al. Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer. *PLoS One.* 2012;7(9):e43409.
- Vigouroux F, et al. Peritrapezial osteoarthritis: Inter- and intraobserver reliability of the Allieu classification. *Hand Surg Rehabil.* 2017 Oct;36(5):363-367.
- Pelter MM, et al. Among Unstable Angina and Non-ST-Elevation Myocardial Infarction Patients, Transient Myocardial Ischemia and Early Invasive Treatment Are Predictors of Major In-hospital Complications. *J Cardiovasc Nurs.* 2016;31(4):10-19.
- Beck Gooz M, et al. ADAM17 promotes proliferation of collecting duct kidney epithelial cells through ERK activation and increased glycolysis in polycystic kidney disease. *Am J Physiol Renal Physiol.* 2014;307(5):551-559.
- Swan JS, et al. Responsiveness of the testing morbidities index in colonoscopy. *Value Health.* 2013;16(6):1046-1053.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481